# Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

> **NCT05591027** · PHASE1 · RECRUITING · sponsor: **Oregon Health and Science University** · enrollment: 48 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer's Disease

## Interventions

- **DRUG:** Centella asiatica product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05591027
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-03-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05591027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05591027, "Safety and Target Engagement of Centella Asiatica in Cognitive Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05591027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*